Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Aflibercept to treat retinopathy of prematurity: need for more research

Journal of Perinatology (2024)Cite this article

Subjects

Abstract

Until recently, the standard care for retinopathy of prematurity (ROP) was destructive treatment of the peripheral avascular retina, most often using laser therapy. Now, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have been included in recommendations for treatment-warranted ROP. The three anti-VEGF agents used to treat ROP are bevacizumab, ranibizumab, and aflibercept and clinical trials using, a variety of treatment strategies, have shown all three are efficacious and easy to administer. Intravitreal Bevacizumab is most used in the US, and ranibizumab has been approved for ROP use in Europe. In 2023, the FDA approved aflibercept for treatment of severe ROP. We summarize the clinical trial results and provide a side-by-side comparisons of the three drugs. Despite FDA approval of the use of aflibercept to treat ROP, there is a need for more research as the body of knowledge regarding this agent to treat ROP is limited.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity. an international multicenter study. Ophthamology. 2022;129:1380–8.

    Article  Google Scholar 

  2. Raghuveer TS, Zackula R. Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis. Neoreviews. 2020;21:e249–e263. https://doi.org/10.1542/neo.21-4-e249

    Article  PubMed  Google Scholar 

  3. Hartnett ME, Stahl A. Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity. Ophthalmol Ther. 2023;12:2241–52.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.

    Article  Google Scholar 

  5. Simmons AB, Bretz CA, Wang H, Kunz E, Hajj K, Kennedy C, et al. Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy. Angiogenesis. 2018;21:751–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sauer L, Chandler M, Hartnett ME. Extending peripheral retinal vascularization in retinopathy of prematurity through regulation of VEGF signaling. Am J Ophthalmol. 2023;260:190–9. https://doi.org/10.1016/j.ajo.2023.12.008. PMID: 38141904.

    Article  CAS  PubMed  Google Scholar 

  7. Mintz-Hittner HA, Kennedy KA, Chuang ZA, for the BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, et al. Low and very low dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology. 2022;129:1120–8. https://doi.org/10.1016/j.ophtha.2022.05.019

    Article  PubMed  Google Scholar 

  10. Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birth weight infants with retinopathy of prematurity (RAINBOW): an open label randomized controlled trial. Lancet. 2019;394:1551–59.

    Article  CAS  PubMed  Google Scholar 

  11. Stahl A, Sukgen EA, Wu W-C, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity. the FIREFLEYE randomized clinical trial. JAMA. 2022;328:348–59. https://doi.org/10.1001/jama.2022.10564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Moshfeghi DM. Effect of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: results from the phase 3 BUTTERFLEYE trial. Invest Ophthalmol Vis Sci. 2023;64:5126.

    Google Scholar 

  13. Stahl A, Azuma N, Wu W-C, Lepore D, Sukgen E, Nakanishi H, et al. Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye. 2024; https://doi.org/10.1038/s41433-024-02948-y

  14. Chang E, Josan AS, Purohit R, Patel CK, Xue K. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for treatment of retinopathy of prematurity. Ophthalmology. 2022;129:1389–401. https://doi.org/10.1016/j.ophtha.2022.06.042

    Article  PubMed  Google Scholar 

  15. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005

    Article  CAS  PubMed  Google Scholar 

  16. Wu WC, Lein R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391–7. https://doi.org/10.1001/jamaophthalmol.2014.5373

    Article  PubMed  Google Scholar 

  17. Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254:31–36. https://doi.org/10.1007/s00417-015-2996-0

    Article  CAS  PubMed  Google Scholar 

  18. Huang CY, Lein R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479–87. https://doi.org/10.1007/s00417-017-3878-4

    Article  CAS  PubMed  Google Scholar 

  19. Khalili S, Shifrin Y, Pan J, Belik J, Mireskandari K. The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study. Exp Eye Res. 2018;169:54–59. https://doi.org/10.1016/j.exer.2018.01.020

    Article  CAS  PubMed  Google Scholar 

  20. Kennedy KA, Mintz-Hittner HA, for the BEAT-ROP Co-operative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61–65. https://doi.org/10.1016/j.jaapos.2017.10.006

    Article  PubMed  Google Scholar 

  21. Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5:698–707. https://doi.org/10.1016/S2352-4642(21)00195-4

    Article  CAS  PubMed  Google Scholar 

  22. Marlow N, Reynolds JD, Lepore D, Reynolds AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomized trial. eClinicalMedicine. 2024;71:102567 https://doi.org/10.1016/j.eclinm.2024.102567

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fierson WM, American Academy of Pediatrics Section of Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142:e20183061 https://doi.org/10.1542/peds.2018-3061

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Kansas School of Medicine-Wichita, Wichita, KS, USA

    Talkad S. Raghuveer

  2. Office of Research, University of Kansas School of Medicine-Wichita, Wichita, KS, USA

    R. E. Zackula

  3. Department of Ophthalmology, Stanford University, Palo Alto, CA, USA

    M. E. Hartnett

Authors
  1. Talkad S. Raghuveer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. E. Zackula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. Hartnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TSR and MEH conducted the targeted literature review. REZ provided statistical analysis. TSR drafted the initial manuscript. MEH and REZ provided intellectual input and critically reviewed and revised the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects.

Corresponding author

Correspondence to Talkad S. Raghuveer.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raghuveer, T.S., Zackula, R.E. & Hartnett, M.E. Aflibercept to treat retinopathy of prematurity: need for more research. J Perinatol (2024). https://doi.org/10.1038/s41372-024-01997-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41372-024-01997-1

Search

Advanced search

Quick links